DIARRHEA RELIEF TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
07-03-2017
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
LOPERAMIDE HYDROCHLORIDE
Beschikbaar vanaf:
TEVA CANADA LIMITED
ATC-code:
A07DA03
INN (Algemene Internationale Benaming):
LOPERAMIDE
Dosering:
2MG
farmaceutische vorm:
TABLET
Samenstelling:
LOPERAMIDE HYDROCHLORIDE 2MG
Toedieningsweg:
ORAL
Eenheden in pakket:
6/12/24/48/100/500
Prescription-type:
OTC
Therapeutisch gebied:
ANTIDIARRHEA AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0111332001; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2019-06-21
Productkenmerken
1
PRODUCT MONOGRAPH
DIARRHEA RELIEF
(Loperamide Hydrochloride)
2 mg Tablets
Oral antidiarrheal agent
TEVA CANADA LIMITED
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Date of Revision:
February 28, 2017
Control No. 202633
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................. 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
10
OVERDOSAGE
...............................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 12
STORAGE AND STABILITY
.........................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
......................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 13
PART II: SCIENTIFIC INFORMATION
................................................................... 15
PHARMACEUTICAL INFORMATION
.........................................................................
15
CLINICAL TRIALS
.........................................................................................................
16
DETAILED PHARMACOLOGY
........................
Lees het volledige document
